There is evidence from in vitro and in vivo studies that the enhanced tumour infiltration by T cells might be due to a reduction in vascular endothelial growth factor (VEGF) expression during BRAF inhibitor administration [20,22,35,36,45]. The gene discussed is BRAF; the disease is neoplasm.